NICO

Data from NICO’s ENRICH trial, published in The New England Journal of Medicine, demonstrates functional improvement for minimally-invasive parafascicular surgery (MIPS)

Data Shows Surgery with NICO's Technology is Superior to Standard of Care, Reduces Mortality, and Significantly Decreases Time in Hospital

NICO Corporation Announces World’s First Positive Surgical Trial for the Deadliest Type of Stroke

NICO recognized for pioneering life-saving technologies for neurosurgery & enabling oncology precision medicine.

Strong investor support pushes medtech innovator closer to mission of revolutionizing brain surgery

Shared goal is using high quality live-cell tissue to achieve patient-specific treatment, improved patient outcomes

Collaboration aims to modernize tissue biobanking for improved treatment of GBM and other brain cancers

Your favorite neurosurgery meeting is back in-person!

NICO Announces CE Mark for BrainPath® Non-Disruptive Cranial Access Technology

NICO Announces First Patient Enrolled in Phase 3 Randomized Controlled Trial on Early Intervention of Hemorrhagic Stroke, Deadliest Form of Stroke

NICO Announces Hemorrhagic Stroke Trial Lead by Emory University and Grady Memorial

NICO Corporation Hits $20 million in Capital Raised to Push Final Frontier in Neurosurgery

$10 Million Investment in NICO Corp. to Expand Production of First Product

NICO Launches New Xenon Light Technology Enabling Enhanced Visualization in Minimally Invasive Neurosurgery

Neurosurgery Device Maker Completes $15 Million Capital Raise to Address Increasing Market Demand of New Technologies for Tumor and Stroke

New Evidence Shows Brain Recovery after Traumatic & Spontaneous Intracerebral Hemorrhage using NICO Minimally Invasive BrainPath Approach

New Published Evidence for Deadly High-Grade Gliomas Linked to Improved Survival

New Study Reveals Nearly $12,000 per Patient Economic Benefit for Hospitals Using New Technology for Brain Tumor Removal and Stroke Treatment